2017 American Society of Clinical Oncology Annual Meeting*

Download All
June 2-6, 2017; Chicago, Illinois
Matthew D. Hellmann, MD, and Heather Wakelee, MD, review and share their expert perspectives on key lung cancer findings presented at the 2017 American Society of Clinical Oncology Annual Meeting.
Matthew D. Hellmann, MD
Heather Wakelee, MD

Lung Cancer

Adjuvant gefitinib for up to 2 years achieved superior DFS vs vinorelbine/cisplatin with no cases of interstitial lung disease.

Released: June 7, 2017

Nivolumab with or without ipilimumab associated with durable responses in patients with advanced, previously treated SCLC.

Released: June 7, 2017

Patients with high PD-L1 who started treatment with first-line pembrolizumab achieved better survival outcomes than those starting with first-line chemotherapy.

Released: June 8, 2017

Patients who remained on atezolizumab after progression of disease by RECIST continued to derive benefit.

Released: June 7, 2017

Osimertinib associated with significantly improved CNS disease control vs platinum/pemetrexed in patients with CNS metastases from advanced NSCLC.

Released: June 9, 2017

One half of patients with irAE-related dose interruptions experienced recurrent or new irAEs during immunotherapy retreatment.

Released: June 5, 2017

nab-Paclitaxel–based treatment was active and well tolerated in elderly patients and those with poorer ECOG performance status.

Released: June 5, 2017

Pembrolizumab plus chemotherapy significantly improved ORR and PFS vs chemotherapy alone with comparable safety profile.

Released: June 4, 2017

Matthew D. Hellmann, MD, and Heather Wakelee, MD, examine and discuss key lung cancer and mesothelioma presentations from the 2017 clinical oncology meeting in Chicago.

Matthew D. Hellmann, MD Heather Wakelee, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: August 10, 2017 Expired: No longer available for credit

Nivolumab with and without ipilimumab was associated with 12-week disease control rates > 40% and median OS > 10 months in patients who progressed after 1-2 lines of chemotherapy.

Released: June 9, 2017

In this phase III study, dacomitinib demonstrated superior PFS and DoR, but with increased toxicity, vs gefitinib in treatment-naive patients with advanced NSCLC and EGFR-activating mutations.

Released: June 9, 2017

Alectinib increased median PFS more than 2-fold and delayed CNS progression with favorable toxicity compared with crizotinib.

Released: June 8, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants by
Celgene Corporation
Halozyme Therapeutics
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.